方法：选取2014-01/2016-01我院眼科就诊AMD患者70例80眼，随机分为观察组35例42眼和对照组35例38眼，分别予以康柏西普与曲安奈德玻璃体腔内注射，对比两组的临床疗效、最佳矫正视力(BCVA)、黄斑中心凹视网膜厚度(CRT)、眼压(IOP)及不良反应。

结果：观察组的治疗总有效率为95%，对照组为79%，差异具有统计学意义(P<0.05)； 治疗后3mo，观察组的BCVA显著高于对照组，而CRT、IOP显著低于对照组，差异具有统计学意义(P<0.05)； 观察组的不良反应率为6%，低于对照组的26%，差异具有统计学意义(P<0.05)。

结论：康柏西普治疗高原地区AMD疗效确切，能够有效改善视力及CRT，且不良反应少。

METHODS: A total of 70 cases(80 eyes)with plateau AMD were selected from Jan.2014 to Jan.2016 in our hospital. All the patients were randomly divided into observation group of 35 cases(42 eyes)and the control group of 35 cases(38 eyes)respectively. Conbercept and intravitreal triamcinolone injection were done in two groups. The clinical efficacy, the best corrected visual acuity(BCVA), macular central fovea thickness(CRT), intraocular pressure(IOP)and adverse reactions of the two groups were compared.

RESULTS: The total efficiency of treatment in the observation group(95%)was significantly higher than that of control group(79%)(P<0.05). BCVA of 3mo after the treatment, the observation group was significantly higher than that of the control group. CRT, IOP was significantly lower than that of control group(P<0.05). In observation group, the adverse reaction rate of 6%, which was significantly lower than that of the control group of 26%(P<0.05).

CONCLUSION: Conbercept in the treatment of plateau area AMD patients have stable efficacy. It can effectively improve the visual acuity and CRT. The adverse reactions were less.